Company Information
Singlera Genomics was founded on July 2014. The company is based in La Jolla, CA, USA . The number of employees in Singlera Genomics is less than 50. Singlera genomics is a fast growing company focusing on non-invasive genetic testing.Here is how Singlera Genomics describes itself: "Singlera Genomics - The future of cancer testing today from ctmDNA (circulating tumor methylated DNA)"
Funding & investors
Singlera Genomics has received 3 rounds of venture funding. The total funding amount is around $230M. Last venture funding round was $150M, announced on December, 2020.- Green Pine Capital Partners (Venture capital)
- Prosperico Ventures (Venture capital)
- Lilly Asia Ventures (Venture capital)
- Jointown Pharmaceutical Group
- UCF Medical Investment
- Contact us if you are interested to see all 17 investors
Similar Companies [beta]
- Vividion therapeutics
- Relay therapeutics
- Rapt therapeutics
- Neuraptive therapeutics
- Checkmate pharmaceuticals
- Repare therapeutics
- More...
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
- Active Investors in Wellness
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
- Best Funded Wellness Startups
News
Singlera Genomics - Blog
- The origin of the FDA and the Elixir Sulfanilamide disaster of 1937
- For colorectal cancer, the only good screening test is one that is taken
- The high standard of reimbursed diagnostic tests
- Calculating the odds of undetected colorectal cancer
- DNA Methylation Biomarkers for Cancer – a Measurement Challenge
- Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole
The origin of the FDA and the Elixir Sulfanilamide disaster of 1937 Safe and effective means just that to the Food and Drug Administration A bottle of the Elixir of Sulfanilamide The Pure Food and Drug Act of 1906 The early 1990’s was the age of the Progressive Era, and one key piece [...]
For colorectal cancer, the only good screening test is one that is taken Tests for detecting hidden (“occult”) blood in stool is widely available Screenshot from USPSTF CRC screening video We have discussed before the challenge of raising colorectal cancer screening rates, and the fact that there are many options in addition to [...]
The high standard of reimbursed diagnostic tests The difference between the standards of the FDA and CMS Figure from NAMSA CMS Reimbursement Webinar For a diagnostic test to get the imprimatur of FDA approval, the manufacturer has to cross a number of hurdles. Last week, the IVD consultancy NAMSA gave a web presentation [...]
Calculating the odds of undetected colorectal cancer In a group of 200 adults aged 50 to 75, what are the chances of finding someone with undetected CRC? Many take chances with their health, in particular CRC screening The unscreened population for colorectal cancer is large. According to Exact Sciences (the manufacturer of the [...]
DNA Methylation Biomarkers for Cancer – a Measurement Challenge Although studied for decades, the study of methylated cytosine DNA residues is not a trivial task for clinical in vitro diagnostics The challenge of methylation analysis in clinical diagnostics In the world of diagnostics, the measurement of biological analytes for clinical use trace its [...]
Cover of Forbes 400 Sept 2015 issue: "The Freshman: Elizabeth Holmes leads the class of 2014" Theranos, the FDA, and the Laboratory-Developed Test (LDT) loophole How could Theranos get away with fraud for such a long time? The American television news broadcaster ABC has produced an excellent six-part audio podcast called “The Dropout” [...]
Share:
